Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Arch Biopartners Inc V.ARCH

Alternate Symbol(s):  ACHFF

Arch Biopartners Inc. is a late-stage clinical trial company focused on preventing acute kidney injury. The Company is developing a platform of new drugs to prevent inflammation injury in the kidneys, lungs and liver via the dipeptidase-1 (DPEP1) pathway and are relevant for many common injuries and diseases where organ inflammation is an unmet problem. The Company’s lead drug candidate is LSALT Peptide. The Company is engaged in the clinical development of LSALT Peptide and other DPEP-1 targeting drug candidates for indications where inflammation of the lungs, liver and kidneys is an unmet problem. LSALT Peptide is in a second phase II trial, targeting the prevention and treatment of cardiac surgery-associated acute kidney injury (CS-AKI). The Company has additional technology platforms in its portfolio, which are AB569 and Borg. AB569 is an anti-infective candidate for treating or preventing antibiotic resistant bacterial infections, primarily as a topical treatment for wounds.


TSXV:ARCH - Post by User

Post by C10H12N2on Dec 30, 2021 8:40pm
139 Views
Post# 34272703

Yeah River. Those same talking point were debunked at CEO.CA

Yeah River. Those same talking point were debunked at CEO.CA

You were provided with a list of 22 Patents by Algernon which includes the Chronic Cough. I need not spam your coveted little message board with the particulars. You can catch up after the uplist to Nasdaq. The CEO at Algernon was correct. You like others no very little about what you spout. Cut and paste whatever you want. You still have no in-depth knowledge about stuff you spew. You don't know the facts about uplisting. You were told that as well. You got so pissed off at CEO.CA you landed in their jail cell to cool off. You were in jail talking to yourself. LOL. Now you have one of your wing boys over at Algernon yet again spouting off the same tired out and proven wrong time and again arguments. Like the one about buying Ifenprodil from a website in Japan. Yeah, ok. Now stretch that theory out to buying a million pills or 10 million pills or 100 million pills from that same website. Do you think you won't get flagged by some authority before the shipment touches down in North America? It's an absolutely ridiculous argument that's not embedded in facts reason or international law. Algernon cares less about an individual buying some tiny quantity of pills. The goal fo0r biotech's is to sell in bulk to governments and hospitals by the truckload. You know...like vaccines. It's MACROECONOMICS. It’s not microeconomics. I feel like I'm talking to a bunch of whiny 3rd graders. Carry on...

 
<< Previous
Bullboard Posts
Next >>